[Impact of Bestim on the immunological status and clinical course of ulcer].

What does this source report?

The report describes immune-marker changes, symptom regression and ulcer scarring with adjunctive Bestim.

Population and setting

Patients receiving combined antiulcer treatment; sample size absent from abstract

Evidence type

Uncontrolled human report

Preparation

See the original report; formulation details require verification.

Source language

English indexed abstract; original language:

Title provenance

Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

What are the limitations?

• Sample size, comparator details and quantitative effects require the full report; this is not reliable evidence of standalone efficacy.
• Full methods, reporting completeness and independent replication remain to be appraised.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Review depth: Abstract reviewed

Source access and review scope

Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.

Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.

Source provenance: Original journal report

Open original source or index record ↗

Cite and trace this record

Original source: Tkacheva AG, Kalev OF, Dolgushina AI, Antipina TV. [Impact of Bestim on the immunological status and clinical course of ulcer]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · PMID 16259438 2004.

Molekul research summary: https://molekul.io/research/audit-16259438. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Related compound profiles